dithiothreitol has been researched along with lansoprazole in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kubo, K; Maki, Y; Nagaya, H; Satoh, H | 1 |
| Dinkhauser, P; Fürst, J; Gschwentner, M; Laich, A; Lang, F; Paulmichl, M; Ritter, M; Rossmann, H; Scandella, E; Schmarda, A; Seidler, U; Wöll, E | 1 |
| Sachs, G; Shin, JM | 1 |
| Arikawa, Y; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
4 other study(ies) available for dithiothreitol and lansoprazole
| Article | Year |
|---|---|
Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Dithiothreitol; Dogs; Ethylmaleimide; Female; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Microsomes; Omeprazole; Protons; Pyridines; Sulfhydryl Compounds | 1989 |
The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 3T3 Cells; Animals; Benzimidazoles; Cell Size; Chloride Channels; Dithiothreitol; Electrophysiology; Enzyme Inhibitors; Fibroblasts; Lansoprazole; Mice; Omeprazole; Proton Pump Inhibitors; Pyridines; Stomach; Sulfhydryl Reagents; Thymine Nucleotides | 2000 |
Restoration of acid secretion following treatment with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Dithiothreitol; Enzyme Activation; Enzyme Inhibitors; Gastric Acid; Glutathione; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley; Stomach | 2002 |
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Dithiothreitol; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imidazoles; In Vitro Techniques; Kinetics; Lansoprazole; Ligation; Male; Potassium; Proton Pump Inhibitors; Pylorus; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides; Swine | 2010 |